Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma, one of the affected companies revealed in an SEC ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out its ...

At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...

Bristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates for its CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...